Indian pharma firms receive 34% of FDA warnings this year
These warnings were for misbranding, selling unapproved medicines and violating Current Good Management Practices
Novartis loses patent appeal in landmark suit
Supreme Court upholds amended law that bars patents for insignificant improvements to an existing drug—in this case anti-cancer drug …